Payment overview · 2025
General Payments
$7,636.79
265 reported records · 34 companies
Healthcare provider profile · identity verified
Dean A Le, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · LAKE FOREST, CA · NPI 1982627089
Verified facts
What the public records show
CMS Open Payments records show Dean A Le, M.D. received $7,636.79 in general payments during 2025 across 265 reported records.
UCB, Inc. accounted for 12.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 49 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Briviact, Gamunex-C, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rytary by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Brilinta by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Gamunex-C by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $955.84 | 12.5% | 30 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $657.79 | 8.6% | 17 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $628.94 | 8.2% | 19 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $600.76 | 7.9% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $476.26 | 6.2% | 18 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $451.87 | 5.9% | 21 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $416.52 | 5.5% | 12 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $385.98 | 5.0% | 12 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $294.60 | 3.9% | 8 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$281.74 | 3.7% | 18 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $259.10 | 3.4% | 13 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $243.62 | 3.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $242.26 | 3.2% | 10 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $204.76 | 2.7% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $190.58 | 2.5% | 4 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $174.29 | 2.3% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $172.64 | 2.3% | 14 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $139.50 | 1.8% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $135.12 | 1.8% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $125.00 | 1.6% | 5 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $115.77 | 1.5% | 5 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $68.26 | 0.9% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $66.55 | 0.9% | 4 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $62.94 | 0.8% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $60.27 | 0.8% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $45.83 | 0.6% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.67 | 0.4% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $27.66 | 0.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $24.61 | 0.3% | 1 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $22.09 | 0.3% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $21.58 | 0.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.55 | 0.3% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $17.00 | 0.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.84 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $7,537.79 | 264 |
| Education | $99.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $666.39 | 26 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $628.94 | 19 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $519.54 | 15 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $409.03 | 17 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $389.48 | 11 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $365.35 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $305.55 | 16 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $229.04 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $222.30 | 11 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $222.30 | 11 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $211.60 | 9 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $204.76 | 7 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological | Octapharma USA, Inc. | $188.16 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $179.62 | 7 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $174.29 | 4 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $171.46 | 7 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $139.50 | 5 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $135.12 | 5 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $125.00 | 5 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $124.25 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $122.71 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $122.20 | 6 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $114.98 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $108.19 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $97.86 | 4 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $94.29 | 4 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc., PFIZER INC. | $92.26 | 4 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $68.26 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $66.55 | 4 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $60.27 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $57.67 | 2 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $56.90 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $45.83 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $34.62 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $34.46 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $32.67 | 1 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $30.66 | 1 | 2025 |
Source payment records
|
|||||
| REYVOW Normalized: reyvow |
Drug | Lilly USA, LLC | $30.66 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $28.48 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $27.66 | 1 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| ZEMBRACE SYMTOUCH Normalized: zembrace symtouch |
Drug | Tonix Medicines, Inc. | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| VNS Therapy Normalized: vns therapy |
Device | LivaNova USA, Inc. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| KOSELUGO Normalized: koselugo |
Drug | Alexion Pharmaceuticals, Inc. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 631 | 216 |
| Donepezil Hcl | Donepezil Hcl | 522 | 190 |
| Gabapentin | Gabapentin | 332 | 124 |
| Topiramate | Topiramate | 129 | 45 |
| Levetiracetam | Levetiracetam | 121 | 44 |
| Ropinirole Hcl | Ropinirole Hcl | 121 | 38 |
| Pregabalin | Pregabalin | 117 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 36 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 103 | 33 |
| Clonazepam | Clonazepam | 87 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | 20 |
| Alprazolam | Alprazolam | 85 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 34 |
| Lacosamide | Lacosamide | 80 | 20 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 70 | 23 |
| Meloxicam | Meloxicam | 70 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 23 |
| Baclofen | Baclofen | 67 | 26 |
| Lorazepam | Lorazepam | 65 | 18 |
| Trazodone Hcl | Trazodone Hcl | 64 | 24 |
| Bupropion Xl | Bupropion Hcl | 60 | 18 |
| Propranolol Hcl Er | Propranolol Hcl | 59 | 20 |
| Diazepam | Diazepam | 56 | 27 |
| Divalproex Sodium | Divalproex Sodium | 56 | 20 |
| Lamotrigine | Lamotrigine | 48 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 47 | suppressed |
| Methylprednisolone | Methylprednisolone | 47 | 34 |
| Propranolol Hcl | Propranolol Hcl | 44 | 24 |
| Prednisone | Prednisone | 39 | 20 |
| Tramadol Hcl | Tramadol Hcl | 38 | 15 |
| Zonisamide | Zonisamide | 37 | 16 |
| Galantamine Hbr | Galantamine Hbr | 34 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 12 |
| Brilinta | Ticagrelor | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | 15 |
| Divalproex Sodium Er | Divalproex Sodium | 32 | 13 |
| Risperidone | Risperidone | 32 | suppressed |
| Rytary | Carbidopa/Levodopa | 32 | suppressed |
| Acetazolamide | Acetazolamide | 28 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | 18 |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 24 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 24 | 17 |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 22 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 21 | suppressed |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Briviact | Brivaracetam | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Botox | Onabotulinumtoxina | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 16 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 14 | suppressed |
| Dexamethasone | Dexamethasone | 13 | 11 |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Clobazam | Clobazam | 12 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,636.79 · 265 records | UCB, Inc. | AMYVID, AUSTEDO XR, BOTOX, Briviact, CREXONT, DAXXIFY, EMGALITY, Fintepla, Gamunex-C, Gocovri, HYQVIA, INBRIJA, INFINITY, INGREZZA, KESIMPTA, KISUNLA, KOSELUGO, LEQEMBI, Mavenclad, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus Zunovo, PANZYGA, PONVORY, QULIPTA, REXULTI, REYVOW, Radicava, Rystiggo, Symbravo, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VNS Therapy, VRAYLAR, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, WAINUA, Xeomin, ZAVZPRET, ZEMBRACE SYMTOUCH, ZEPOSIA, ZTLido | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error